Goch, Germany (24^th May 2022) - As a global leader in excipient solutions and services for pharmaceutical and biopharmaceutical drug development, DFE Pharma offers an extensive portfolio of over 200 premium products. Our Biopharma team attends the coming APV Workshop on Protein Aggregation and Immunogenicity, which takes place on May 31^st and June 1^st in Eimeldingen (Germany), ready to share expertise and solutions on the most challenging formulation needs.

DFE Pharma offers (bio)pharmaceutical companies the most optimal functional ingredients for the development of their medicines. With BioHale® Sucrose and BioHale® Trehalose Dihydrate, we provide premium quality excipients for the stabilization of biopharmaceutical formulations.

Our BioHale® portfolio can be used in various administration forms, such as for parenteral, inhalation or ophthalmic route and it is already used in several of the current vaccines against COVID-19, such as the vaccines of the global COVID-19 vaccination market leader – among other biologic treatments.

To learn more about our portfolio, technical support and continuous innovation, please visit our booth at APV Workshop on Protein Aggregation and Immunogenicity.